JPH03167194A - Purification of lecithin - Google Patents
Purification of lecithinInfo
- Publication number
- JPH03167194A JPH03167194A JP30625389A JP30625389A JPH03167194A JP H03167194 A JPH03167194 A JP H03167194A JP 30625389 A JP30625389 A JP 30625389A JP 30625389 A JP30625389 A JP 30625389A JP H03167194 A JPH03167194 A JP H03167194A
- Authority
- JP
- Japan
- Prior art keywords
- lecithin
- water
- endotoxin
- solution
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000787 lecithin Substances 0.000 title claims abstract description 65
- 235000010445 lecithin Nutrition 0.000 title claims abstract description 65
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 title claims abstract description 64
- 229940067606 lecithin Drugs 0.000 title claims abstract description 64
- 238000000746 purification Methods 0.000 title description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims description 19
- 239000011259 mixed solution Substances 0.000 abstract description 17
- 238000002347 injection Methods 0.000 abstract description 7
- 239000007924 injection Substances 0.000 abstract description 7
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 239000002158 endotoxin Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 239000007787 solid Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000239218 Limulus Species 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 235000002597 Solanum melongena Nutrition 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000002510 pyrogen Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 239000003463 adsorbent Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011013 endotoxin removal Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- -1 alkalis Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 229940099578 hydrogenated soybean lecithin Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011046 pyrogen test Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000000476 thermogenic effect Effects 0.000 description 1
- 238000001132 ultrasonic dispersion Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Abstract
Description
[産業上の利用分野】
本発明は、医薬品分野、特に注射剤の用途に好適なエン
ドトキシンフリーのレシチンを得る精製方法に関する.
[従来の技術]
レシチンは代表的なリン脂質であり、リポソーム(脂質
2分子膜小包体)を形成するので、薬剤のカプセルとし
て用いることができ、しかもこのようなリン脂質2分子
構造は生体膜の主要成分であり、またレシチンは人体に
対する安全性が高いので、近年新しいドラッグ・デリバ
リー・システムの一つとしてレシチンをリポソーム製剤
へ応用する試みが盛んに行われている.
リポソーム製剤の投与方法としては種々の方法があり、
現在静脈注射投与が主流であるが、静脈注射投与する場
合,注射剤中にパイロジエン(発熱性物質)が含まれて
いないことが必須である.パイロジェンとは発熱性を示
す高分子性物質であり,それが喘乳類の血管内に入ると
一過性の発熱を引き起こし、時には当該動物をショック
死させることもある有害物質である.パイロジェンの中
でもダラム陰性菌細胞壁の外膜成分であるリポ多糖(L
PS)を主成分とするエンドトキシン(内毒素)は、パ
イロジエンの中でも特に発熱性が高く,普遍的に存在し
ているものである.このため日本薬局方では発熱性物質
の試験項目を設け、製剤中のパイロジェン量を規制して
いる.従って、リポソーム製剤の基材として用いられる
レシチンは発熱性物質試験の結果が陰性のものでなけれ
ばならない.
エンドトキシンの除去方法としては,■加熱滅菌処理,
■化学的処理,■吸着剤処理、■膜ろ過処理、■蒸留処
理等が知られているが,そのうち■の加熱滅菌処理は、
エンドトキシンが熱に対し比較的安定であるため,25
0℃で一時間加熱する必要があり,また■の化学的処理
も酸、アルカリや過酸化物を使用するため、レシチン自
体をも分解させてしまうので処理することが困難であり
、■の蒸留処理も物理的に極めて困難である.また,■
の吸着剤処理としては活性炭、あるいはイオン交換樹脂
を用いることが知られているが,いずれも効果が少なく
、試料成分のロスが大きいという問題があった.さらに
、■の膜ろ過処理としては、除菌フィルター(0.2ミ
クロンフィルター)ろ過、あるいは限外ろ過が知られて
いるが、除菌フィルターの効果は少なく、限外ろ過は通
常水溶液で行われるため水に難溶であるレシチンの処理
は困難であるという問題があった.即ち、既存のエンド
トキシンの除去方法は、般に水あるいはアミノ酸、糖、
抗生物質、ビタミン等の水溶性物質に対するもので、水
に難溶であるレシチンからエンドトキシンを除去するた
めの有効な方法はまだ知られていなかった.また、油溶
性物質中のエンドトキシンを定量する場合、通常被検物
質を有機溶剤に溶解させ、エンドトキシンフリー水で抽
出した水溶液をリムルス試験等で定量するが、被検物質
がレシチンの場合,レシチンとエンドトキシンの相溶性
によりエンドトキシンフリー水による抽出が困難なため
、正確な定量ができないという問題もあった.〔発明が
解決しようとする課題〕
本発明は、これら上記の問題点を解決し、レシチンに影
響を及ぼすことなく,エンドトキシンフリーのレシチン
を得ることを目的としている.[Industrial Application Field] The present invention relates to a purification method for obtaining endotoxin-free lecithin suitable for use in the pharmaceutical field, particularly for injections. [Prior art] Lecithin is a typical phospholipid that forms liposomes (lipid bilayer membrane packages), so it can be used as capsules for drugs. Since lecithin is a major component of liposomes and is highly safe for the human body, there have been many attempts in recent years to apply lecithin to liposome preparations as a new drug delivery system. There are various methods of administering liposome preparations.
Currently, intravenous administration is the mainstream, but when administering intravenous injections, it is essential that the injection does not contain pyrogens (pyrogenic substances). Pyrogen is a polymeric substance that exhibits pyrogenicity, and when it enters the blood vessels of wheeze mammals, it causes a temporary fever and is a harmful substance that can sometimes cause the animal to die from shock. Among the pyrogens, lipopolysaccharide (L
Endotoxin (endotoxin), whose main component is PS), is particularly highly thermogenic among pyrogienes and is ubiquitous. For this reason, the Japanese Pharmacopoeia has established test items for pyrogenic substances and regulates the amount of pyrogen in preparations. Therefore, lecithin used as a base material for liposome preparations must have a negative pyrogen test result. Methods for removing endotoxin include ■heat sterilization,
■Chemical treatment, ■Adsorbent treatment, ■Membrane filtration treatment, ■Distillation treatment, etc. are known, but among these, ■Heat sterilization treatment is
Because endotoxin is relatively stable against heat, 25
It is necessary to heat at 0℃ for one hour, and the chemical treatment in (■) uses acids, alkalis, and peroxides, which also decomposes the lecithin itself, making it difficult to process. Processing is also physically extremely difficult. Also, ■
It is known that activated carbon or ion exchange resins are used as adsorbent treatments, but both have the problem of low effectiveness and large loss of sample components. In addition, as membrane filtration treatment (■), sterilization filter (0.2 micron filter) filtration or ultrafiltration is known, but the sterilization filter has little effect, and ultrafiltration is usually performed with an aqueous solution. Therefore, there was a problem in that it was difficult to process lecithin, which is poorly soluble in water. That is, existing endotoxin removal methods generally use water, amino acids, sugars,
There was no known effective method for removing endotoxins from lecithin, which is poorly soluble in water and is used for water-soluble substances such as antibiotics and vitamins. In addition, when quantifying endotoxin in oil-soluble substances, the test substance is usually dissolved in an organic solvent and the aqueous solution extracted with endotoxin-free water is quantified using a Limulus test, etc.; however, when the test substance is lecithin, it is Due to the compatibility of endotoxins, extraction with endotoxin-free water was difficult, making accurate quantification impossible. [Problems to be Solved by the Invention] The present invention aims to solve the above-mentioned problems and obtain endotoxin-free lecithin without affecting lecithin.
本発明者らは上記の目的を達或するために鋭意検討を重
ねた結果、レシチンをアルコールまたは水/アルコール
混合溶液に溶解させた後,エンドトキシンに親和性を持
つヒスチジンをリガンドとして固定化させた固定化ヒス
チジンと接触させることにより、エンドトキシンを選択
的に吸着除去でき、しかもこの方法によればレシチンに
何等悪影響を及ぼさず,きわめて安全性が高いことを見
いだし本発明に到達した.
本発明において処理するレシチンは,既存の天然系ある
いは合成系のあらゆるレシチンを用いることができるが
、本発明の目的である医薬品分野へ利用するためには高
純度に精製されたレシチンを用いることが好ましい.こ
こで、レシチンの精製法は既存のいかなる精製法であっ
ても差し支えない.例えば、溶剤抽出法、アセトン再沈
法、カラムクロマト分離法等のそれぞれ単独の精製方法
でも良いし、それらの数種類を組み合わせた精製方法で
も良い.
本発明において用いられる固定化ヒスチジンは,担体に
スベーサーを介して、エンドトキシンに親和性を持つヒ
スチジンをリガンドとして固定化させたものが好ましく
、担体としては高分子多糖類、合成高分子担体,無機担
体等を用いることができるが、セルロース、アガロース
のような高分子多糖類が好適である.このような固定化
ヒスチジンとして市販されている物では、例えばセファ
ロース(架橋アガロースゲル)にヘキサメチレンジアミ
ンをスペーサーとしてヒスチジンを共有結合させたダイ
セル化学工業■製「パイロセツブ』がある.
本発明においてレシチンを固定化ヒスチジンで処理する
方法としては.固定化ヒスチジンを充填剤としてカラム
に充填した後、レシチン溶液を溶出させるカラムクロマ
トグラフィー法、または吸着剤としてレシチン溶液に添
加し撹拌した後,ろ過して固定化ヒスチジンを除去する
という方法などを用いることができ,エンドトキシンは
カラム中または溶液中で選択的に吸着され除去される.
使用した固定化ヒスチジンは洗浄等の処理により再生し
、繰り返し使用することができる.本発明において使用
するアルコールとしては、メタノール、エタノールおよ
びインブロバノールを用いることができ、それぞれを単
独で用いても良いし混合して用いても良い.
本発明において使用する水/アルコール混合溶液の組成
は、処理するレシチンを完全に溶解する組成であればい
かなる組成であっても良いが、水の割合が多い場合脱溶
剤が困難になるため,水/エタノール=O〜10/90
−100容量%が望ましい.また、水/アルコール混合
溶液中のレシチン濃度は、処理するレシチンを完全に溶
解する濃度であればいかなる組成であっても良いが、作
業性を良くするために5〜20重量%であることが望ま
しい.
[発明の効果】
本発明のエンドトキシンフリーのレシチンの製造法は、
レシチンをアルコールまたは水/アルコール混合溶液に
溶解させた後,固定化ヒスチジンと接触させることによ
って、効果的にレシチン中のエンドトキシンを吸着除去
する事ができ,安全性が高いので、医薬品分野、特に注
射剤への利用が可能となるため、産業上極めて益するこ
と大である.
また、本発明のエンドトキシン除去処理法は、固定化ヒ
スチジンをカラムに充填し、レシチンの水/エタノール
混合溶液を通過させるという方法、またはレシチンの水
/エタノール混合溶液中に固定化ヒスチジンを添加し撹
拌・ろ過するとレ)う、いずれも比較的簡単な方法であ
るため、大量生産が可能となり、また吸着体として用い
られる固定化ヒスチジンは再生により繰り返し使用でき
るので工業的に極めて有用である.The present inventors conducted intensive studies to achieve the above objective, and after dissolving lecithin in alcohol or a mixed water/alcohol solution, immobilized histidine, which has an affinity for endotoxin, as a ligand. The present invention was achieved by discovering that endotoxin can be selectively adsorbed and removed by contacting with immobilized histidine, and that this method has no adverse effect on lecithin and is extremely safe. The lecithin to be treated in the present invention can be any existing natural or synthetic lecithin, but in order to be used in the pharmaceutical field, which is the purpose of the present invention, it is recommended to use highly purified lecithin. preferable. Here, the lecithin purification method may be any existing purification method. For example, a purification method such as solvent extraction, acetone reprecipitation, column chromatography, etc. may be used alone, or a combination of several of these methods may be used. The immobilized histidine used in the present invention is preferably one in which histidine, which has an affinity for endotoxin, is immobilized as a ligand on a carrier via a substrate, and the carrier may be a polymer polysaccharide, a synthetic polymer carrier, or an inorganic carrier. However, high molecular weight polysaccharides such as cellulose and agarose are preferred. Examples of commercially available immobilized histidine include "Pyrosetsub" manufactured by Daicel Chemical Industries, Ltd., in which histidine is covalently bonded to Sepharose (cross-linked agarose gel) using hexamethylene diamine as a spacer. Methods for treatment with immobilized histidine include column chromatography, in which immobilized histidine is packed into a column as a packing material and the lecithin solution is eluted, or it is added to the lecithin solution as an adsorbent, stirred, filtered, and fixed. A method such as removing oxidized histidine can be used, and endotoxin is selectively adsorbed and removed in a column or solution.
The used immobilized histidine can be regenerated by washing and other treatments and used repeatedly. As the alcohol used in the present invention, methanol, ethanol, and inbrobanol can be used, and each may be used alone or in a mixture. The composition of the water/alcohol mixed solution used in the present invention may be any composition as long as it completely dissolves the lecithin to be treated, but if the proportion of water is high, it will be difficult to remove the solvent. /ethanol=O~10/90
-100% by volume is desirable. Furthermore, the lecithin concentration in the water/alcohol mixed solution may be of any composition as long as it completely dissolves the lecithin to be treated, but it is preferably 5 to 20% by weight in order to improve workability. desirable. [Effect of the invention] The method for producing endotoxin-free lecithin of the present invention includes the following steps:
By dissolving lecithin in alcohol or a water/alcohol mixed solution and then contacting it with immobilized histidine, endotoxin in lecithin can be effectively adsorbed and removed. Because of its high safety, it is widely used in the pharmaceutical field, especially for injections. This will be of great industrial benefit as it will be possible to use it as a drug. In addition, the endotoxin removal treatment method of the present invention includes a method of filling a column with immobilized histidine and passing a lecithin water/ethanol mixture solution, or adding immobilized histidine to a lecithin water/ethanol mixture solution and stirring. Filtration is a relatively simple method that allows mass production, and the immobilized histidine used as an adsorbent can be reused repeatedly, making it extremely useful industrially.
本発明を実施例および比較例を用いて具体的に説明する
.
なお、ここに実施例および比較例で使用する器具は、す
べて250℃で2時間以上乾熱滅菌、あるいは0.2モ
ルのNaOH水溶液( 2 0 vol%のエタノール
を含む)に12時間以上浸漬し、エンドトキシンフリー
の水(注射用蒸留水)で洗浄してから使用した.
また、用いた被処理レシチンはいずれもリムルス試験(
使用試薬:生化学工業■製バイロデイツプ)に陽性であ
ることを確認した後使用した.また,リムルス試験を行
う場合、レシチン中のエンドトキシンを注射用蒸留水で
抽出することが困難なため、すべて被検レシチンを20
mg精秤し注射用蒸留水をlmA加えた後、50〜60
℃にて30分超音波分散させた水縣濁溶液を検定試料と
して用いた.
また、すべての処理はクラス100のクリーンベンチに
て行った.
叉』l劣」エ
50mI2のビーカーに、レシチン純度99,O重量%
の精製卵黄レシチンを2.06g秤取り,次いで水/メ
タノール=5/9 5容量%の混合溶液をレシチン濃度
が10重量%となるように加え完全に溶解した.次にこ
のレシチン溶液を、あらかじめ固定化ヒスチジン(ダイ
セル化学工業■製「パイロセップJ)10mβを充填し
た内径ICmのオーブンガラス力ラムにて、溶出速度1
.Omlll分(SV=6)で溶出させた後、水/メタ
ノール= 5/9 5容量%の混合溶液30ml2を1
.OmAl分で溶出させた.溶出液をすべて100mβ
ナスフラスコに回収し、エバボレーターにて脱溶剤し固
形分1.98g C回lIv率96.1%)を得た.得
られた固形分中のレシチン純度は99.0重量%であり
、リムルス試験(使用試薬:生化学工業■製バイロデイ
ツブ)で陰性(N.D.)であった.
及五旦1
50mgのビーカーに、レシチン純度99.1重量%の
大豆水添レシチンを2.12g秤取り、次いで水/エタ
ノール=5/95容量%の混合溶液をレシチン濃度が5
重量%となるように加え完全に溶解した、次にこのレシ
チン溶液を、あらかじめ固定化ヒスチジン(ダイセル化
学工業■製「パイロセップJ)10mlを充填した内径
1cmのオーブンガラス力ラムにて、溶出速度0. 5
mβ/分(SV=3)で溶出させた後、水/エタノール
=5/95容量%の混合溶液3 0mI2を0. 5r
r+j!/分で溶出させた.溶出液をすべて100ml
ナスフラスコに回収し、エバボレーターにて脱溶剤し,
固形分2.05g (回収率96.7%)を得た.得ら
れた固形分中のレシチン純度は99.1重量%であり、
リムルス試験(使用拭薬:生化学工業■製バイ口デイツ
ブ)で陰性(N.D.)であった。
4五五』
50mQのビーカーに,レシチン純度99.8重量%の
合成DMPC (ジミリストイルフオスファチジルコリ
ン)を2.10g秤取り、次いで水/イソブロバノール
=5/9 5容量%の混合溶液をレシチン濃度が5重量
%となるように加え完全に溶解した、次にこのレシチン
溶液を、あらかじめ固定化ヒスチジン(ダイセル化学工
業■製「バイロセップJ)Ionβを充填した内径1c
mのオーブンガラスカラムにて、溶出速度0,5mβ/
分(SV=3)で溶出させた後、水/イソブロバノール
=5/95容量%の混合溶液30mβを0.5mβ/分
で溶出させた.溶出液をすべて100mIlナスフラス
コに回収し、エバポレーターにて脱溶剤し固形分2.0
5g (回収率97.6%》を得た.得られた固形分中
のレシチン純度は99.8重量%であり,リムルス試験
(使用試薬:生化学工業■製バイロデイップ)で陰性(
N.D.)であった.
及五旦1
100mI2のビーカーに、レシチン純度99.6重量
%の合成DPPC (ジバルミトイルフォスファチジル
コリン)を10.04g秤取り,次いで水/エタノール
=0.2/99.8容量%の混合溶液をレシチン濃度が
20重量%となるように加え完全に溶解した、次にこの
レシチン溶液を、あらかじめ固定化ヒスチジン(ダイセ
ル化学工業■製「バイロセップJ)10mAを充填した
内径lcmのオーブンガラス力ラムにて、溶出速度2.
0mI2/分(SV=12)で溶出させた後、水/エタ
ノール==Q,2/99.8容量%の混合溶液30mβ
を2.0mβ/分で溶出させた.溶出液をすべて100
mlナスフラスコに回収し,エバポレーターにて脱溶剤
し固形分9.87g《回収率98.3%》を得た.mら
れた固形分中のレシチン純度は99.6重量%であり,
リムルス拭験(使用試薬:生化学工業物製パイロディッ
プ》で躊性(N.D.)であった.
裏1口糺互
100mβのビーカーに、レシチン純度99.6重量%
の合成DPPC (ジバルミトイルフォスファチジルコ
リン)を10.11g秤取り、次いで水/エタノール=
0.2/99.8容量%の混合溶液をレシチン濃度が2
0重量%となるように加え完全に溶解した、次にこのレ
シチン溶液に、あらかじめパイロセップを水/エタノー
ル=0.2/99.8容量%の混合溶液で1 0mI2
となるように湿潤させたものを添加し、25℃で1時間
撹拌した.次にPTFE製0.2ミクロンの除菌フィル
ターにて溶出速度2.Omitl分でろ過させた後、水
/エタノール=0.2/99.8容量%の混合溶液30
mlを2.0m!/分洗浄ろ過させた.ろ液をすべて1
00rr+42ナスフラスコに回収し、エバボレーター
にて脱溶剤し固形分9.83g (回収率97.2%)
を得た.得られた固形分中のレシチン純度は99.6重
量%であり、リムルス試験(使用試薬:生化学工業■製
バイロディップ)で陰性(N.D.)であった.止1t
ユ
50n+j!のビーカーに、レシチン純度99.6重量
%の合成DPPC (ジバルミトイルフオスファチジル
コリン)を10.09g秤取り、次いで水/エタノール
=Q,2/99.8容量%の混合溶液をレシチン濃度が
20重量%となるように加え完全に溶解した.次にこの
レシチン溶液を,PTFE製0.2ミクロンの除菌フィ
ルターにて、溶出速度2.0mj2/分でろ過させた後
、水/エタノール=0.2/99.8容量%の混合溶液
30mβを2.0mβ/分洗浄ろ過させた.ろ液をすべ
て100mI2ナスフラスコに回収し、エバボレーター
にて脱溶剤し固形分9.91g(回収率98.2%)を
得た.得られた固形分中のレシチン純度は99.6重量
%であったが,リムルス試験(使用試薬:生化学工業■
製パイロディップ)で陽性であった.
これらの各実施例および比較例の結果から明らかなよう
に、固定化ヒスチジンで処理する本発明方法によりレシ
チンを精製した場合、レシチンに悪影響を及ぼすことな
く、効率よくエンドトキシンを除去できるのに対し、固
定化ヒスチジンによる処理を行なわず、除菌フィルター
でろ過しただけでは、効率よくエンドトキシンを除去す
ることができないことがわかる.The present invention will be specifically explained using examples and comparative examples. All instruments used in the Examples and Comparative Examples were dry heat sterilized at 250°C for 2 hours or more, or immersed in a 0.2M NaOH aqueous solution (containing 20 vol% ethanol) for 12 hours or more. and washed with endotoxin-free water (distilled water for injection) before use. In addition, all of the treated lecithins used were tested in the Limulus test (
Reagent used: Seikagaku Kogyo ■ Virodip) was used after confirming that it was positive. In addition, when performing the Limulus test, since it is difficult to extract endotoxin in lecithin with distilled water for injection, all test lecithin is
After accurately weighing mg and adding lmA of distilled water for injection, 50 to 60
A water suspension solution subjected to ultrasonic dispersion at ℃ for 30 minutes was used as the test sample. All treatments were performed on a class 100 clean bench. In a 50mI2 beaker, lecithin purity 99% by weight
2.06 g of purified egg yolk lecithin was weighed out, and then a mixed solution of water/methanol = 5/9 5% by volume was added so that the lecithin concentration was 10% by weight to completely dissolve it. Next, this lecithin solution was passed through an oven glass force ram with an inner diameter ICm filled with 10 mβ of immobilized histidine (Pyrosep J manufactured by Daicel Chemical Industries, Ltd.) at an elution rate of 1.
.. After eluting with Omllll minutes (SV = 6), 30 ml of water/methanol = 5/9 5% by volume mixed solution was added to 1
.. It was eluted with OmAl. All eluates were 100mβ
It was collected in an eggplant flask, and the solvent was removed using an evaporator to obtain a solid content of 1.98 g (C conversion rate: 96.1%). The purity of lecithin in the obtained solid content was 99.0% by weight, and the result was negative (N.D.) in the Limulus test (reagent used: Viroditub, manufactured by Seikagaku Corporation). Weigh out 2.12g of hydrogenated soybean lecithin with a lecithin purity of 99.1% by weight into a 50mg beaker, and then add a mixed solution of water/ethanol = 5/95% by volume to a 50mg beaker with a lecithin concentration of 5%.
% by weight and completely dissolved. Next, this lecithin solution was placed in an oven glass force ram with an inner diameter of 1 cm and filled with 10 ml of immobilized histidine ("Pyrosep J" manufactured by Daicel Chemical Industries, Ltd.) in advance at an elution rate of 0. .5
After elution at mβ/min (SV=3), 30 mI2 of a mixed solution of water/ethanol = 5/95% by volume was added at 0.0 mI2. 5r
r+j! /min. 100ml of all eluate
Collect in an eggplant flask, remove solvent with an evaporator,
A solid content of 2.05 g (recovery rate 96.7%) was obtained. The lecithin purity in the obtained solid content was 99.1% by weight,
The Limulus test (wiping agent used: Baiguchi Datsubu manufactured by Seikagaku Kogyo ■) was negative (N.D.). Weigh out 2.10g of synthetic DMPC (dimyristoylphosphatidylcholine) with lecithin purity of 99.8% by weight into a 50mQ beaker, then add a mixed solution of water/isobrobanol = 5/9 5% by volume. This lecithin solution was added to a lecithin concentration of 5% by weight and completely dissolved. Next, this lecithin solution was added to a 1cm tube with an inner diameter filled with immobilized histidine ("Virosep J" manufactured by Daicel Chemical Industries, Ltd.) in advance.
m oven glass column, elution rate 0.5 mβ/
After elution at a rate of 0.5 mβ/min (SV=3), 30 mβ of a mixed solution of water/isobrobanol = 5/95% by volume was eluted at a rate of 0.5 mβ/min. All the eluate was collected in a 100 ml eggplant flask, and the solvent was removed using an evaporator to reduce the solid content to 2.0.
5 g (recovery rate: 97.6%). The lecithin purity in the obtained solid content was 99.8% by weight, and the Limulus test (reagent used: Virodip, manufactured by Seikagaku Corporation) was negative (
N. D. )Met. Weigh out 10.04g of synthetic DPPC (divalmitoylphosphatidylcholine) with lecithin purity of 99.6% by weight into a 100mI2 beaker, and then add water/ethanol = 0.2/99.8% by volume. The mixed solution was added so that the lecithin concentration was 20% by weight and completely dissolved. Next, this lecithin solution was placed in an oven glass oven with an inner diameter of 1 cm filled with 10 mA of immobilized histidine (Vyrosep J manufactured by Daicel Chemical Industries, Ltd.). In the ram, elution rate 2.
After elution at 0 mI2/min (SV=12), 30 mβ of a mixed solution of water/ethanol==Q, 2/99.8% by volume
was eluted at 2.0 mβ/min. All eluates are 100%
Collected in a ml eggplant flask, the solvent was removed using an evaporator to obtain a solid content of 9.87 g (recovery rate 98.3%). The lecithin purity in the solid content was 99.6% by weight,
Limulus wiping test (reagent used: Seikagaku Kogyo Co., Ltd. PyroDip) showed stagnation (N.D.). Lecithin purity 99.6% by weight was placed in a 100 mβ beaker with one back opening.
Weigh out 10.11g of synthesized DPPC (divalmitoylphosphatidylcholine), then water/ethanol =
A mixed solution of 0.2/99.8% by volume with a lecithin concentration of 2
Add Pyrosep to this lecithin solution to give a total concentration of 0% by weight and dissolve completely. Next, add Pyrosep to this lecithin solution in advance with a mixed solution of water/ethanol = 0.2/99.8% by volume at 10 ml2.
The mixture was moistened so that the mixture was wetted and stirred at 25°C for 1 hour. Next, a PTFE 0.2 micron sterilization filter was used to elute at a rate of 2. After filtering with Omitl, a mixed solution of water/ethanol = 0.2/99.8% by volume 30
2.0m for ml! Washed and filtered for 1 minute. All filtrate 1
Collected in a 00rr + 42 eggplant flask and removed the solvent using an evaporator, solid content 9.83g (recovery rate 97.2%)
I got it. The lecithin purity in the obtained solid content was 99.6% by weight, and the Limulus test (reagent used: Virodip, manufactured by Seikagaku Corporation) was negative (ND). Stop 1t
Yu50n+j! Weigh out 10.09 g of synthetic DPPC (divalmitoylphosphatidylcholine) with lecithin purity of 99.6% by weight into a beaker, then add a mixed solution of water/ethanol = Q, 2/99.8% by volume to lecithin. It was added to a concentration of 20% by weight and completely dissolved. Next, this lecithin solution was filtered through a 0.2 micron sterilization filter made of PTFE at an elution rate of 2.0 mj2/min, and then a mixed solution of water/ethanol = 0.2/99.8% by volume (30 mβ) was added. was washed and filtered at 2.0 mβ/min. All of the filtrate was collected in a 100 mI2 eggplant flask, and the solvent was removed using an evaporator to obtain a solid content of 9.91 g (recovery rate 98.2%). The purity of lecithin in the obtained solid content was 99.6% by weight, but the purity of lecithin in the obtained solid content was 99.6% by weight.
Pyro-dip) was positive. As is clear from the results of these Examples and Comparative Examples, when lecithin is purified by the method of the present invention in which it is treated with immobilized histidine, endotoxin can be efficiently removed without adversely affecting lecithin. It can be seen that endotoxin cannot be efficiently removed simply by filtering with a sterilization filter without treatment with immobilized histidine.
Claims (1)
液に溶解し、固定化ヒスチジンで処理することを特徴と
するレシチンの精製方法。1. A method for purifying lecithin, which comprises dissolving lecithin in alcohol or a mixed water/alcohol solution and treating the solution with immobilized histidine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP30625389A JP2775929B2 (en) | 1989-11-22 | 1989-11-22 | Purification method of lecithin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP30625389A JP2775929B2 (en) | 1989-11-22 | 1989-11-22 | Purification method of lecithin |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH03167194A true JPH03167194A (en) | 1991-07-19 |
JP2775929B2 JP2775929B2 (en) | 1998-07-16 |
Family
ID=17954848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP30625389A Expired - Fee Related JP2775929B2 (en) | 1989-11-22 | 1989-11-22 | Purification method of lecithin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2775929B2 (en) |
-
1989
- 1989-11-22 JP JP30625389A patent/JP2775929B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2775929B2 (en) | 1998-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0592989B1 (en) | Process of the selective and quantitative removal or preparation of tumor necrosis factor (TNF) and lipopolysaccharides (LPS) of aqueous solutions | |
DE102006055558A1 (en) | Adsorbent for removing endotoxins from solutions comprises a ligand in the form of an amine-functional molecule in which some of the amine groups are modified with an amine-reactive molecule | |
US5136032A (en) | Method for separating phosphopolyol compounds using a separating agent | |
US6699386B2 (en) | Endotoxin adsorbent, and a method of removing endotoxin by using the same | |
KR930000269B1 (en) | Seperating membrane and seperation method | |
JP6467652B2 (en) | Endotoxin adsorbent | |
DE69837993T2 (en) | ADSORBENTS FOR TOXIC SHOCKSYNDROME TOXIN-1, METHOD FOR REMOVING TOXIN BY ADSORBTION | |
EP3298129B1 (en) | Method of preparing universal blood product | |
DE3926539C2 (en) | ||
JP2775929B2 (en) | Purification method of lecithin | |
DE4113602A1 (en) | Highly selective endotoxin adsorber - consists of bead-like water swollen cellulose prod. contg. polyethylene-imine as the functional ligand | |
RU2641924C1 (en) | Sorption material, method of its production and method of its application | |
CA2249548A1 (en) | Endotoxin-specific membranes | |
DK154048B (en) | PROCEDURE FOR CLEANING LIPOSOM SUSPENSIONS FOR NON-CONTAINED MEDICINAL PRODUCTS | |
WO2000008463A2 (en) | Immunoadsorber for removing endotoxins | |
DE19740770A1 (en) | Microfiltration layer for removing endotoxins from liquids | |
CN109772269A (en) | A kind of endotoxin absorbent and its preparation method and application | |
JPH07816A (en) | Endotoxin adsorbent | |
JP3239239B2 (en) | Cellulose-based microporous membrane with endotoxin adsorption ability | |
JPH05345724A (en) | Production of oral medicine solution containing sennoside compounds as active ingredient | |
JPH01196294A (en) | Elimination of pyrogen from superoxide dismutase | |
JP3226529B2 (en) | Exothermic substance adsorbent | |
JPH01196295A (en) | Elimination of pyrogen from prourokinase | |
JP3075595B2 (en) | Method for producing endotoxin-free drugs | |
JP2908455B2 (en) | Pyrogen removal method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080501 Year of fee payment: 10 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090501 Year of fee payment: 11 |
|
LAPS | Cancellation because of no payment of annual fees |